プラスミノーゲンアクチベーター, PA
WordNet
- (biology) any agency bringing about activation; a molecule that increases the activity of an enzyme or a protein that increases the production of a gene product in DNA transcription
- an inactive form of plasmin that occurs in plasma and is converted to plasmin by organic solvents
PrepTutorEJDIC
- personal assistant個人秘書 / public address [system]
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/05/14 15:31:00」(JST)
[Wiki en表示]
|
This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2009) (Learn how and when to remove this template message) |
A plasminogen activator is a serine protease which converts plasminogen to plasmin, thus promoting fibrinolysis.
Types include:
- Tissue plasminogen activator
- Urokinase
It is inhibited by plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2.
Endopeptidases: serine proteases/serine endopeptidases (EC 3.4.21)
|
|
Digestive enzymes |
- Enteropeptidase
- Trypsin
- Chymotrypsin
- Elastase
|
|
Coagulation |
- factors: Thrombin
- Factor VIIa
- Factor IXa
- Factor Xa
- Factor XIa
- Factor XIIa
- Kallikrein
- PSA
- KLK1
- KLK2
- KLK3
- KLK4
- KLK5
- KLK6
- KLK7
- KLK8
- KLK9
- KLK10
- KLK11
- KLK12
- KLK13
- KLK14
- KLK15
- fibrinolysis: Plasmin
- Plasminogen activator
- Tissue plasminogen activator
- Urinary plasminogen activator
|
|
Complement system |
- Factor B
- Factor D
- Factor I
- MASP
- C3-convertase
|
|
Other immune system |
- Chymase
- Granzyme
- Tryptase
- Proteinase 3/Myeloblastin
|
|
Venombin |
|
|
Other |
- Acrosin
- Prolyl endopeptidase
- Pronase
- Proprotein convertases
- Prostasin
- Reelin
- Subtilisin/Furin
- Streptokinase
- S1P
- Cathepsin
|
|
Plasminogen |
PDB rendering based on 4dur.
|
Available structures |
PDB |
Ortholog search: PDBe, RCSB |
List of PDB id codes |
1B2I, 1BML, 1BUI, 1CEA, 1CEB, 1DDJ, 1HPJ, 1HPK, 1I5K, 1KI0, 1KRN, 1L4D, 1L4Z, 1PK4, 1PKR, 1PMK, 1QRZ, 1RJX, 2DOH, 2DOI, 2KNF, 2L0S, 2PK4, 3UIR, 4A5T, 4CIK, 4DCB, 4DUR, 4DUU, 5HPG
|
|
|
Identifiers |
Symbols |
PLG ; DKFZp779M0222 |
External IDs |
OMIM: 173350 MGI: 97620 HomoloGene: 55452 ChEMBL: 1801 GeneCards: PLG Gene |
EC number |
3.4.21.7 |
Gene ontology |
Molecular function |
• serine-type endopeptidase activity
• receptor binding
• protein binding
• serine-type peptidase activity
• protein domain specific binding
• apolipoprotein binding
|
Cellular component |
• extracellular region
• extracellular space
• plasma membrane
• cell surface
• platelet alpha granule lumen
• extrinsic component of external side of plasma membrane
• extracellular exosome
• blood microparticle
|
Biological process |
• platelet degranulation
• proteolysis
• blood coagulation
• negative regulation of cell proliferation
• negative regulation of cell-substrate adhesion
• extracellular matrix disassembly
• platelet activation
• extracellular matrix organization
• fibrinolysis
• cellular protein metabolic process
• tissue remodeling
• negative regulation of fibrinolysis
• positive regulation of fibrinolysis
• negative regulation of cell-cell adhesion mediated by cadherin
|
Sources: Amigo / QuickGO |
|
RNA expression pattern |
|
|
|
More reference expression data |
Orthologs |
Species |
Human |
Mouse |
Entrez |
5340 |
18815 |
Ensembl |
ENSG00000122194 |
ENSMUSG00000059481 |
UniProt |
P00747 |
P20918 |
RefSeq (mRNA) |
NM_000301 |
NM_008877 |
RefSeq (protein) |
NP_000292 |
NP_032903 |
Location (UCSC) |
Chr 6:
160.7 – 160.75 Mb |
Chr 17:
12.38 – 12.42 Mb |
PubMed search |
[1] |
[2] |
|
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
|
|
Antiplatelet drugs |
Glycoprotein IIb/IIIa inhibitors |
- Abciximab
- Eptifibatide
- Tirofiban
- Roxifiban
- Orbofiban
|
|
ADP receptor/P2Y12 inhibitors |
- Thienopyridines
- Clopidogrel
- Prasugrel
- Ticlopidine
- Nucleotide/nucleoside analogs
- Cangrelor
- Elinogrel
- Ticagrelor
|
|
Prostaglandin analogue (PGI2) |
- Beraprost
- Iloprost
- Prostacyclin
- Treprostinil
|
|
COX inhibitors |
- Acetylsalicylic acid/Aspirin#
- Aloxiprin
- Carbasalate calcium
- Indobufen
- Triflusal
|
|
Thromboxane inhibitors |
- Thromboxane synthase inhibitors
- Dipyridamole (+Aspirin)
- Picotamide
- Receptor antagonists
|
|
Phosphodiesterase inhibitors |
- Cilostazol
- Dipyridamole
- Triflusal
|
|
Other |
- Cloricromen
- Ditazole
- Vorapaxar
|
|
|
Anticoagulants |
Vitamin K antagonists
(inhibit II, VII, IX, X) |
- Coumarins: Acenocoumarol
- Coumatetralyl
- Dicoumarol
- Ethyl biscoumacetate
- Phenprocoumon
- Warfarin#
- 1,3-Indandiones: Clorindione
- Diphenadione
- Phenindione
- Other: Tioclomarol
|
|
Factor Xa inhibitors
(with some II inhibition) |
Heparin group/
glycosaminoglycans/
(bind antithrombin) |
- Low molecular weight heparin
- Bemiparin
- Certoparin
- Dalteparin
- Enoxaparin
- Nadroparin
- Parnaparin
- Reviparin
- Tinzaparin‡
- Oligosaccharides
- Fondaparinux
- Idraparinux§
- Heparinoids
- Danaparoid
- Dermatan sulfate
- Sulodexide
|
|
Direct Xa inhibitors |
- Xabans
- Apixaban
- Betrixaban†
- Darexaban§
- Edoxaban
- Otamixaban§
- Rivaroxaban
|
|
|
Direct thrombin (IIa) inhibitors |
- Bivalent: Hirudin
- Bivalirudin
- Desirudin
- Lepirudin
- Univalent: Argatroban
- Dabigatran
- Melagatran‡
- Ximelagatran‡
|
|
Other |
- Antithrombin III
- Defibrotide
- Protein C
- Ramatroban
- REG1
|
|
|
Thrombolytic drugs/
fibrinolytics |
- Plasminogen activators: r-tPA
- Alteplase
- Reteplase
- Tenecteplase
- UPA
- Anistreplase
- Monteplase
- Streptokinase#
- Other serine endopeptidases: Ancrod
- Brinase
- Fibrinolysin
|
|
Non-medicinal |
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Reperfusion Therapy in the Acute Management of Ischemic Stroke.
- Lin MP1, Sanossian N2.
- Cardiology clinics.Cardiol Clin.2015 Feb;33(1):99-109. doi: 10.1016/j.ccl.2014.09.009.
- Reperfusion, or restoration of blood flow, is an effective means of reducing disability in the setting of acute stroke. Reperfusion therapies, such as intravenous thrombolysis or endovascular and interventional procedures, fit within the existing stroke system of care. There are currently 4 devices
- PMID 25439334
- Expression and anticancer activity analysis of recombinant human uPA1‑43-melittin.
- Su M1, Chang W1, Cui M1, Lin Y1, Wu S1, Xu T1.
- International journal of oncology.Int J Oncol.2015 Feb;46(2):619-26. doi: 10.3892/ijo.2014.2750. Epub 2014 Nov 13.
- The present study is focused on expression of a target fusion protein which can be used in ovarian cancer target therapy. It aimed to construct human urokinase-type plasminogen activator (uPA)1‑43-melittin eukaryotic expression vector to express recombinant human uPA1‑43-melittin (rhuPA1‑43-me
- PMID 25394558
- Predictive value of plasma biomarkers for mortality and organ failure development in patients with acute respiratory distress syndrome.
- Cartin-Ceba R1, Hubmayr RD2, Qin R3, Peters S2, Determann RM4, Schultz MJ4, Gajic O2.
- Journal of critical care.J Crit Care.2015 Feb;30(1):219.e1-7. doi: 10.1016/j.jcrc.2014.09.001. Epub 2014 Sep 6.
- PURPOSE: To evaluate the predictive value of 6 different biomarkers in the development of multiple-organ failure (MOF) and mortality in a contemporary prospective cohort of acute respiratory distress syndrome (ARDS).METHODS: Patients with ARDS admitted to a tertiary referral center during an 8-month
- PMID 25261280
Japanese Journal
- 畑山 さや香,緒方 利安,大川 将和 [他]
- Brain and nerve : 神経研究の進歩 64(10), 1175-1179, 2012-10-00
- NAID 40019457094
- Observational Investigation of Thrombolysis With the Tissue-Type Plasminogen Activator Monteplase for Acute Pulmonary Embolism in Japan
- NIWA Akihiro,NAKAMURA Mashio,HARADA Natsumi,MUSHA Takashi
- Circulation journal : official journal of the Japanese Circulation Society 76(10), 2471-2480, 2012-09-25
- … Background: In Japan, the safety and efficacy of thrombolytic therapy using tissue-type plasminogen activator for acute pulmonary embolism (PE) in the real world remain unclear. …
- NAID 10030875222
- 循環器内科医が遭遇する,大動脈解離による脳梗塞 (特集 循環器内科医が遭遇する脳梗塞)
Related Links
- Plasminogen activatorとは?goo Wikipedia (ウィキペディア) 。出典:Wikipedia(ウィキペディア)フリー百科事典。 Plasminogen activatorとは - goo Wikipedia (ウィキペディア) gooトップ サイトマップ スタートページに設定 RSS ヘルプ ...
- Mimuro J (1991). "[Type 1 plasminogen activator inhibitor: its role in biological reactions]". Rinsho Ketsueki 32 (5): 487–9. PMID 1870265. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M et al. (2002). "Plasminogen ...
★リンクテーブル★
[★]
- 英
- endothelium (Z)
- 関
- 血管
Table 10-1. Endothelial Cell Properties and Functions
|
Maintenance of Permeability Barrier
|
Elaboration of Anticoagulant, Antithrombotic, Fibrinolytic Regulators
|
prostacyclin
|
thrombomodulin
|
heparin-like molecules
|
plasminogen activator
|
Elaboration of Prothrombotic Molecules
|
Von Willebrand factor
|
Tissue factor
|
Plasminogen activator inhibitor
|
Extracellular Matrix Production (Collagen, Proteoglycans)
|
Modulation of Blood Flow and Vascular Reactivity
|
Vasconstrictors: endothelin, ACE
|
Vasodilators: NO, prostacyclin
|
Regulation of Inflammation and Immunity
|
IL-1, IL-6, chemokines
|
Adhesion molecules: VCAM-1, ICAM, E-selectin P-selectin
|
Histocompatibility antigens
|
Regulation of Cell Growth
|
Growth stimulators: PDGF, CSF, FGF
|
Growth inhibitors: heparin, TGF-β
|
Oxidation of LDL
|
[★]
- 英
- plasminogen activator, PA
- 関
- プラスミノーゲン活性化因子、プラスミノゲン
[show details]
[★]
- 英
- plasminogen activator PA
- 同
- プラスミノゲン活性化因子
- 関
[★]
プラスミノーゲン活性化因子インヒビター1、プラスミノーゲンアクチベーターインヒビター1
- 関
- PAI-1
[★]
プラスミノゲンアクチベータインヒビター-1
[★]
プラスミノゲンアクチベーター放出障害
[★]